

12<sup>a</sup>  
ACTUALIZACIÓN  
en el TRATAMIENTO  
**LEUCEMIA**  
AGUDA 2023



del 5 al 7  
OCT  
2023

**Dr. Jordi Esteve**

*Hospital Clínic de Barcelona, Spain*

Consultant, head of Hematology department at Hospital Clínic of Barcelona and Associate Professor at University of Barcelona. Clinical research focused on the analysis and design of risk-adapted protocols in AML, within the Spanish Cooperative group CETLAM (current chair, Group for the Study and Treatment of Acute Myeloid Leukemia), and development of new therapeutic strategies. Leader of a team devoted to translational research in AML in the Research Foundation IDIBAPS (Institut de Investigacions Biomèdiques August Pi i Sunyer). Co-chair of the molecular markers subcommittee of the Acute Leukemia Working Party (European Society for Blood and Marrow Transplantation, EBMT), aimed to analyze the impact of molecular markers on the outcome of HSCT in acute leukemia. Member of the European Hematology Association-Scientific Working Group (EHA-SWG) on AML. Member of main national (Catalan Society of Hematology/SCHH, Spanish Society of Hematology & Hemotherapy/SEHH) and international Hematology associations (European Hematology Association/EHA, EBMT, and American Society of Hematology/ASH).